New Delhi: Biotechnology firm Biocon on Monday said it has extended its alliance with Cuba-based CIM for an integrated programme in immunology.
The company has strengthened its partnership with the Havana-based Centre of Molecular Immunology (CIM) for an integrated anti-body programme in immunology, Biocon said in a statement.
Both Biocon and CIM have collaborated for almost a decade to develop biotechnology products for chronic diseases. Two drugs have already been approved due to this collaboration for medical use in India and other territories, it said.
The parties are now looking to create an innovative product pipeline focused on auto-immune diseases and cancer and have identified an anti-body, ‘Anti-CD6’, which targets lymphocytes, the key players in the immuno-pathology of an auto-immune disease, it added.
“This ‘Anti-CD6’ targeting anti-body is a first in class molecule, which has recently transited to advanced clinical trials for the treatment of psoriasis and rheumatoid arthritis patients,” Biocon Limited CMD Kiran Mazumdar Shaw said.
Shares of Biocon were trading at Rs358.35 on the Bombay Stock Exchange in late afternoon trade on Monday, up 1.79% from the previous close.